China Resources Boya Bio-pharmaceutical Group Co.,Ltd Stock

Equities

300294

CNE100001FF1

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-21 pm EDT 5-day change 1st Jan Change
31.51 CNY -0.41% Intraday chart for China Resources Boya Bio-pharmaceutical Group Co.,Ltd +2.94% -6.44%
Sales 2024 * 1.91B 264M Sales 2025 * 2.08B 287M Capitalization 15.72B 2.17B
Net income 2024 * 542M 74.82M Net income 2025 * 596M 82.27M EV / Sales 2024 * 8.23 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 7.57 x
P/E ratio 2024 *
29.1 x
P/E ratio 2025 *
26.4 x
Employees 1,444
Yield 2024 *
0.96%
Yield 2025 *
1.08%
Free-Float 16.25%
More Fundamentals * Assessed data
Dynamic Chart
China Resources Boya Bio-Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2023 CI
China Resources Boya Bio-Pharmaceutical Group Co.,Ltd Proposes Cash Dividend CI
CR Boya Bio-Pharmaceutical's 2023 Profit Falls on Lower Revenue MT
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CR Boya Bio-Pharmaceutical Signs 29.5 Million Yuan Construction Contract for Blood Products Facility MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. completed the acqyusution 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd. CI
CR Boya Bio-Pharmaceutical's January-September Profit Increases MT
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire an 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd for CNY 260 million CI
China Resources Pharmaceutical Commercial Group Company Limited completed the acquisition of 75% stake in Guangdong Fuda Pharmaceutical Co., Ltd. from China Resources Boya Bio-pharmaceutical Group Co., Ltd.. CI
China Resources Pharmaceutical Commercial Group Company Limited agreed to acquire 75% stake in Guangdong Fuda Pharmaceutical Co., Ltd. from China Resources Boya Bio-pharmaceutical Group Co., Ltd. for approximately CNY 360 million. CI
China Resources Pharmaceutical's Subsidiaries Log Increases in H1 Profits MT
China Resources Boya's H1 Attributable Profit Jumps 16.9% MT
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China Resources Boya Bio-pharmaceutical Group's Q1 Profit Rises MT
More news
1 day-0.41%
1 week+2.94%
Current month+9.71%
1 month+16.79%
3 months+13.35%
6 months+9.37%
Current year-6.44%
More quotes
1 week
30.37
Extreme 30.37
32.14
1 month
26.68
Extreme 26.68
32.14
Current year
22.91
Extreme 22.91
34.09
1 year
22.91
Extreme 22.91
38.98
3 years
22.91
Extreme 22.91
56.80
5 years
22.08
Extreme 22.08
58.15
10 years
8.88
Extreme 8.8844
58.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 93-11-05
Director of Finance/CFO 42 21-08-31
Director/Board Member 56 93-11-05
Members of the board TitleAgeSince
Director/Board Member 61 21-02-02
Chief Executive Officer 57 93-11-05
Director/Board Member 56 93-11-05
More insiders
Date Price Change Volume
24-04-23 31.17 -1.08% 3,906,015
24-04-22 31.51 -0.41% 4,949,545
24-04-19 31.64 +2.10% 4,961,426
24-04-18 30.99 -0.19% 4,700,233
24-04-17 31.05 +0.49% 5,911,511

End-of-day quote Shenzhen S.E., April 21, 2024

More quotes
China Resources Boya Bio-pharmaceutical Group Co Ltd, formerly Boya Bio-pharmaceutical Group Co Ltd, is a China-based company principally engaged in the research, development, production and distribution of blood products. The Company's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The Company's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The Company also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The Company distributes its products mainly in domestic market.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31.17 CNY
Average target price
32.45 CNY
Spread / Average Target
+4.10%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300294 Stock